A Phase Ib, Randomized, Open-label, Multi-center Study to Evaluate the Preliminary Efficacy and Safety of Furmonertinib Mesilate in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutation
Latest Information Update: 23 Nov 2023
At a glance
- Drugs Firmonertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms FAVOUR
- Sponsors Allist Pharmaceuticals
- 30 Oct 2023 According to an ArriVent Biopharma media release, interim results from this trial demonstrated furmonertinib has promising anti-tumor activity as a single agent with a well-tolerated safety profile in the first-line and previously treated patients.
- 30 Oct 2023 According to an ArriVent Biopharma media release, based on interim results from this trial, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for furmonertinib for the treatment of patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
- 12 Sep 2023 Results (As of the data cutoff date of January 18, 2023,n= 79 )presented at the 24th World Conference on Lung Cancer